JPRN-jRCT2080224007已完成1 期
Phase 1 and 2 study of tamibarotene and decitabine for relapse and refractory pediatric solid tumor
Osaka City General Hospital, Junichi Hara0 个研究点目标入组 57 人开始时间: 2018年8月16日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 57
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 3age old 至 <= 30age old（—）
- 性别
- All
入选标准
- •1) Aged 3 to 30 years old at study entry
- •2) Phase 1:Histologically proven either sarcoma, blastoma, germ cell tumors, or central nervous system tumor except malignant lymphoma
- •Phase 2:Histologically proven neuroblastoma and experienced high-dose chemotherapy with an autologous hematopoietic stem cell transplantation
- •3) More than one regimen of chemotherapy including standard therapeutic agents(Patients without options of the standard treatment)
- •4) Found a lesion by either imaging inspection, bone marrow examination, or tumor marker diagnosis(It doesn't matter whether the presence or absence of measurable lesions defined by RECIST but remission cases are not targeted)
- •5) PS(Karnofsky or Lansky)>=50%
- •6) The periods as below have passed since the last use of anti-tumor agents
- •(1) 7 days or more have passed if dosing method which is continuously-administered more than once in 3 days with no rest period
- •(2) 14 days or more have passed if other dose methods were used
- •7) The periods as below have passed since the last irradiation date
- •a) 12 weeks or more if radiation fields contain either whole brain and spine, whole abdomen, whole lung, whole body, or more than 50% of pelvis
- •b) 14 days or more if irradiation fields contain less than 3 vertebrae and localized irradiation to other fields
- •c) 6 weeks or more if irradiation fields are none of the above applies
- •8) No difficulty to take a soft capsule or a tablet
- •9) Clinical data within 14 days
- •(1) Neutrophil count>=1500/mm3(no administration of G-CSF within 3 days before blood-collecting)
- •(2) Platelet count>=7.5x10^4/mm3(no blood transfusion within 3 days before blood-collecting)
- •(3) Total bilirubin<=1.5mg/dl
- •(4) AST(GOT)<=100U/L
- •(5) ALT(GPT)<=100U/L
- •(6) TG<=300mg/dl
- •(7) Serum creatinine(Cre)<=ULN of children reference value x3(no dialysis)
- •(8) Hemoglobin(Hb)A1c<=6.2%(NGSP)
- •10) No abnormalities which require an intervention in 12-lead electrocardiogram tested within 28 days before the study entry
- •11) Written informed consent from a patient and/or a legal guardian
排除标准
- •1) Synchronous cancer and asynchronous cancer with 5 years of disease-free survival except carcinoma in situ or intramucosal carcinoma
- •2) In patients having a brain tumor or metastasis to brain, a symptom with the intracranial hypertension is poor in control
- •3) Active infection requires systemic treatment
- •4) Respiratory failure requiring oxygen administration
- •5) Medical history and complication of thrombosis
- •6) Woman who are or may be pregnancy, or are impossible to use effective methods of contraception from 1 month prior to the administration to 2 years after the final dose of treatment. Woman with impossible to discontinue breast-feeding from 1 month prior to the administration to 2 years after the final dose of treatment. Men who are impossible to use effective methods of contraception during the administration and 6 months after the final dose of treatment.
- •7) Patients considered to be difficult to participate because of psychiatric illness or complication of psychological symptom
- •8) Patients with history of hypersensitivity to the study drugs
- •9) Patients otherwise considered to be ineligible for enrollment in the study by an investigator
研究者
相似试验
已完成
1 期
DACTBT-P1/P2Phase 1: Relapse and refractory pediatric solid tumor, Phase 2: Relapse and refractory neuroblastomasolid tumor, neuroblastomaJPRN-jRCT2051190055Hara Junichi57
招募中
1 期
Decitabine/carboplatin combination treatment protocol for metastatic melanomaMetastatic melanomaCancer - Malignant melanomaACTRN12616000440426niversity of Newcastle10
招募中
2 期
Phase II study of gemcitabine, carboplatin and dexamethasone with or without rituximab for patients with relapsed or refractory non-Hodgkin's lymphomarelapsed or refractory non-Hodgkin's lymphomaJPRN-UMIN000015998Gifu University Hospital20
进行中（未招募）
不适用
Dose-finding study of the substance clofarabine in combination with fixed doses of cytarabine and idarubicine as therapy for patients with acute myeloid leukemia and high risk for treatment failure (CIARA)Patients with acute myeloid leukemia (AML) and high risk for induction failureMedDRA version: 17.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2010-021719-18-DEHannover Medical School
尚未招募
2 期
Phase IIa study of tamibarotene in patients with ADPKDAutosomal Dominant Polycystic Kidney DiseaseJPRN-jRCT2011230055Hayashi Ayuto70